Becton Dickinson
About: Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
Employees: 74,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
278% more call options, than puts
Call options by funds: $792M | Put options by funds: $209M
25% more funds holding in top 10
Funds holding in top 10: 20 [Q4 2024] → 25 (+5) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 128 | Existing positions closed: 128
2% less repeat investments, than reductions
Existing positions increased: 589 | Existing positions reduced: 600
4% less capital invested
Capital invested by funds: $60.4B [Q4 2024] → $57.9B (-$2.5B) [Q1 2025]
1.76% less ownership
Funds ownership: 89.78% [Q4 2024] → 88.02% (-1.76%) [Q1 2025]
3% less funds holding
Funds holding: 1,597 [Q4 2024] → 1,551 (-46) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Morgan Stanley Patrick Wood 50% 1-year accuracy 8 / 16 met price target | 12%upside $196 | Overweight Maintained | 6 May 2025 |
Piper Sandler Jason Bednar 35% 1-year accuracy 14 / 40 met price target | 5%upside $185 | Neutral Downgraded | 2 May 2025 |
Stifel Rick Wise 45% 1-year accuracy 15 / 33 met price target | 28%upside $224 | Buy Maintained | 2 May 2025 |
Barclays Travis Steed 33% 1-year accuracy 2 / 6 met price target | 49%upside $261 | Overweight Maintained | 7 Apr 2025 |
Financial journalist opinion
Based on 29 articles about BDX published over the past 30 days









